Companies/Protagenic Therapeutics, Inc.

Company profile

Protagenic Therapeutics, Inc.

NASDAQ: PTIX · Healthcare · Biotechnology

PublicHQ New York City, NY · New YorkCIK 0001022899Reports USD

#1166 of 1,422 Healthcare companies by revenue

EA Score

——

FH —DQ 28GM —SS 20

v0.1 · 25/100 weight · pillars only

↑ balance-sheet leverage, Piotroski F · ↓ workforce scale, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

-100.0%

Net income (FY)

-$5.5M

Employees

as of 2026-08-27

Market cap

$1.7M

as of 2026-08-27

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02024

Net income-$5.5M-$5.5M2024

Operating income-$5.7M-$5.7M2024

Total assets$2.0M$2.0M2024

Liabilities$942.8k$942.8k2024

Equity$1.0M$1.0M2024

Revenue trend

FY2015 – FY2024 · USD

FY15

FY16

FY21

FY22

FY23

FY24

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Protagenic Therapeutics, Inc.’s revenue?

Protagenic Therapeutics, Inc. booked $0 in FY2024 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Lobe Sciences Ltd.42D Dakshidin Corporation31D Decoy Therapeutics Inc.31D Welsis Corp.20D Azitra, Inc.29D Acro Biomedical Co., Ltd.17D

Neighbors

New York →

JPMorgan Chase & Co.$182.4B72B Morgan Stanley$34.3B61C The Goldman Sachs Group, Inc.——Philip Morris International Inc.$40.6B86A American Express Company$41.3B78B+Citigroup Inc.$85.2B55C

Key facts

CEOGaro H. Armen

SectorHealthcare

IndustryBiotechnology

HeadquartersNew York City, NY

ExchangeNASDAQ: PTIX

Employees2

IPO date2021-04-27

Latest filings

8-K2026-08-20 10-Q2026-08-19 10-K2026-08-14 8-K2026-04-07 10-Q2026-03-09 8-K2026-03-03 8-K2026-02-24 8-K2026-01-05

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.